← Russell 3000 cross-section

TGTX TG THERAPEUTICS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$8.4bn
Revenue TTM
$800m
Net income TTM
$442m
Free cash flow
$17m
Composite score
45.5
Sector rank
#801

Valuation

P / E
19.0
EV / EBITDA
62.9
EV / sales
10.7
FCF yield
0.21%
Earnings yield vs 10-yr
0.53pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
55.2%
EBITDA margin
17.1%
ROE
73.1%
ROIC
17.1%
Revenue growth
76.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In addition, we will receive tiered double-digit royalties on net product sales up to 30%. We will continue to invest in our research and development programs and in selling, general and administrative activities to support our commercialization efforts, while maintaining discipline around overall expense growth relative to revenue. The actual amount of cash needed to support these strategic initiatives will depend on many factors, including: Cost of Revenue Cost of revenue consists primarily of royalties owed to our licensing partner for BRIUMVI sales, materials and third-party manufacturing costs, freight, distribution and logistics expenses, and overhead costs associated with our supply c …TG THERAPEUTICS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →